SOPHiA GENETICS (SOPH) Expected to Release Earnings on Tuesday

SOPHiA GENETICS (NASDAQ:SOPH) is expected to post its Q2 2026 results before the market opens on Tuesday, August 4th. Analysts expect the company to announce earnings of ($0.21) per share and revenue of $21.7210 million for the quarter. Parties are encouraged to explore the company’s upcoming Q2 2026 earning report page for the latest details on the call scheduled for Tuesday, August 4, 2026 at 8:00 AM ET.

SOPHiA GENETICS (NASDAQ:SOPH) last posted its quarterly earnings data on Tuesday, May 5th. The company reported ($0.27) EPS for the quarter, missing the consensus estimate of ($0.23) by ($0.04). The firm had revenue of $21.69 million during the quarter, compared to analyst estimates of $20.40 million. SOPHiA GENETICS had a negative net margin of 44.48% and a negative return on equity of 62.74%. On average, analysts expect SOPHiA GENETICS to post $-1 EPS for the current fiscal year and $-0 EPS for the next fiscal year.

SOPHiA GENETICS Trading Down 1.2%

Shares of SOPH stock opened at $5.65 on Tuesday. SOPHiA GENETICS has a fifty-two week low of $2.92 and a fifty-two week high of $6.77. The company has a debt-to-equity ratio of 1.05, a quick ratio of 1.90 and a current ratio of 2.06. The stock’s fifty day moving average is $5.40 and its two-hundred day moving average is $5.08. The firm has a market capitalization of $473.98 million, a P/E ratio of -10.87 and a beta of 0.96.

Insiders Place Their Bets

In other news, CTO Abhimanyu Verma sold 5,285 shares of SOPHiA GENETICS stock in a transaction on Monday, July 6th. The stock was sold at an average price of $5.10, for a total transaction of $26,953.50. Following the transaction, the chief technology officer owned 192,171 shares in the company, valued at $980,072.10. The trade was a 2.68% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Philippe Menu sold 5,000 shares of the business’s stock in a transaction dated Monday, July 13th. The shares were sold at an average price of $5.70, for a total transaction of $28,500.00. Following the transaction, the insider directly owned 228,387 shares in the company, valued at approximately $1,301,805.90. The trade was a 2.14% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders sold 171,711 shares of company stock worth $935,813. 4.88% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On SOPHiA GENETICS

Several institutional investors and hedge funds have recently bought and sold shares of SOPH. Squarepoint Ops LLC acquired a new stake in shares of SOPHiA GENETICS during the 3rd quarter worth approximately $49,000. Quadrature Capital Ltd purchased a new position in SOPHiA GENETICS in the fourth quarter worth approximately $54,000. XTX Topco Ltd acquired a new stake in SOPHiA GENETICS during the fourth quarter worth $55,000. Susquehanna International Group LLP acquired a new stake in SOPHiA GENETICS during the third quarter worth $88,000. Finally, Polen Capital Management LLC purchased a new stake in SOPHiA GENETICS in the fourth quarter valued at $102,000. 31.59% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of equities research analysts have recently commented on the stock. HC Wainwright began coverage on shares of SOPHiA GENETICS in a research report on Monday, July 20th. They issued a “buy” rating and a $12.00 target price for the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of SOPHiA GENETICS in a research note on Friday, July 17th. Zacks Research upgraded shares of SOPHiA GENETICS to a “hold” rating in a report on Tuesday, July 21st. Finally, BTIG Research reissued a “buy” rating and issued a $8.00 target price on shares of SOPHiA GENETICS in a research note on Monday, June 15th. Three investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average price target of $9.00.

SOPHiA GENETICS Company Profile

SOPHiA GENETICS SA is a data-driven medicine company founded in 2011 and headquartered in La Tène, Switzerland. The firm develops and operates a cloud-native software platform designed to standardize and analyze complex genomic and radiomic data. Its core offering, the SOPHiA DDM™ platform, leverages artificial intelligence and machine learning algorithms to help healthcare institutions, laboratories and biopharmaceutical partners derive actionable insights from next-generation sequencing and medical imaging datasets.

The SOPHiA DDM™ platform supports a range of clinical applications, including oncology, hereditary diseases and rare genetic disorders.